MorphoSys AG (MOR) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET
Company Participants
Julia Neugebauer - IR
Jean-Paul Kress - CEO
Malte Peters - Chief Research & Development Officer
Sung Lee - CFO
Joseph Horvat - U.S. General Manager
Conference Call Participants
Jason Butler - JMP Securities
James Gordon - JPMorgan
Xian Deng - Berenberg
Philippa Pritchard - Morgan Stanley
Victor Floc'h - Stifel
Julia Neugebauer
Ladies and gentlemen, good afternoon or good morning. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys, and it is my pleasure to welcome you to our Half Year 2022 Financial Results Conference Call.
With me on the call today are Jean-Paul Kress, Chief Executive Officer; Sung Lee, Chief Financial Officer; Malte Peters, Chief Research and Development Officer; and Joe Horvat, U.S. General Manager.
Before we begin, I'd like to remind you on Slide 2 that some of our statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans and expectations for the compounds in our pipeline as well as the development plans of our collaboration partners. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys' 20-F and annual report, all for the year ended December 31, 2021, and from time to time in other SEC documents of MorphoSys. It is important to keep in mind that our statements in this webcast speak as of today.
On Slide 3, you'll find the agenda for today's call. Jean-Paul will begin with an overview and will give an outlook. Joe then will provide a commercial update and Malte will provide an update on our development pipeline before turning the call to Sung for
- Read more current MOR analysis and news
- View all earnings call transcripts